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Background: Members of the Acinetobacter calcoaceticus-baumannii (Acb) complex are important opportunistic bacterial patho-
gens and present significant therapeutic challenges in the treatment of nosocomial infections. In the present study, we investigat-
ed the integrons and various genes involved in resistance to carbapenems, aminoglycosides, and fluoroquinolones in 56 imipen-
em-nonsusceptible Acb complex isolates.
Methods: This study included 44 imipenem-nonsusceptible A. baumannii, 10 Acinetobacter genomic species 3, and 2 Acinetobacter 
genomic species 13TU strains isolated in Daejeon, Korea. The minimum inhibitory concentrations (MICs) were determined by Etest. 
PCR and DNA sequencing were used to identify the genes that potentially contribute to each resistance phenotype. 
Results: All A. baumannii isolates harbored the blaOXA-51-like gene, and 21 isolates (47.7%) co-produced OXA-23. However, isolates of 
Acinetobacter genomic species 3 and 13TU only contained blaIMP-1 or blaVIM-2. Most Acb complex isolates (94.6%) harbored class 1 in-
tegrons, armA, and/or aminoglycoside-modifying enzymes (AMEs). Of particular note was the fact that armA and aph(3´)-Ia were 
only detected in A. baumannii isolates, which were highly resistant to amikacin (MIC50≥256) and gentamicin (MIC50≥1,024). In all 
44 A. baumannii isolates, resistance to fluoroquinolones was conferred by sense mutations in the gyrA and parC. However, sense 
mutations in parC were not found in Acinetobacter genomic species 3 or 13TU isolates. 
Conclusions: Several differences in carbapenem, aminoglycoside, and fluoroquinolone resistance gene content were detected 
among Acb complex isolates. However, most Acb complex isolates (87.5%) possessed integrons, carbapenemases, AMEs, and mu-
tations in gyrA. The co-occurrence of several resistance determinants may present a significant threat. 
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INTRODUCTION
Acinetobacter spp. are ubiquitous in the environment and 
have emerged as important opportunistic pathogens that 
cause nosocomial infections [1]. Currently, more than 30 
named and unnamed species of Acinetobacter have been 
identified by DNA-DNA hybridization [2]. Acinetobacter 
baumannii, which is the most frequently identified species 
from clinical infections and outbreaks, is genetically closely 
related and phenotypically similar to 2 other clinical spe-
cies, namely, Acinetobacter genomic species (gen. sp.) 3 and 
13TU and to Acinetobacter calcoaceticus, a soil bacterium. 
This close similarity led to the proposal that these species 
should be grouped together in the so-called A. calcoaceti-
cus-A. baumannii (Acb) complex [3]. With the exception of 
A. calcoaceticus, all members of this complex have been re-
ported to be involved in nosocomial infections and are known 
to have the ability to spread within hospitals [4].
Acb complex has now become a major cause of hospital-
acquired infections worldwide due to its remarkable propen-
sity to rapidly acquire determinants of resistance to a wide 
range of antibacterial agents [5]. In particular, increasing 
resistance to carbapenems has been observed worldwide in 
the past decade. Carbapenemase production is the best-de-
scribed mechanism of resistance to carbapenems, and vari-266     www.kjlm.org
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ous metallo-β-lactamases (MBLs) and OXA-type carbapen-
emases have been isolated from Acb complex strains world-
wide [6-8]. In some instances, carbapenemase genes, such 
as blaIMP, blaVIM, blaGIM, or blaSIM, are located within class 1 
integrons and lead to carbapenem resistance. Multidrug-re-
sistant Acb complex strains have been known to acquire their 
antimicrobial resistance genes via class 1 integrons that carry 
single or multiple gene cassettes [9]. 
Aminoglycoside resistance genes, such as acetyltransfer-
ase (aac), phosphotransferase (aph), and adenylyltransfer-
ase (aad), are also typically found within integron gene cas-
settes [10]. In addition, Acb complex strains carry various 
types of aminoglycoside-modifying enzymes (AMEs) and 
16S rRNA methylases, which confer resistance to aminogly-
cosides [11].
Increases in the number of fluoroquinolone-resistant Acb 
complex strains are mediated primarily by spontaneous mu-
tations in the quinolone resistance-determining regions (QR-
DRs) of either DNA gyrase (gyrA), topoisomerase IV (parC), 
or both [12].
Although the Acb complex has been recognized as an im-
portant opportunistic pathogen associated with life-threat-
ening nosocomial infections and hospital outbreaks, there 
is a relative paucity of data on the number and type of resis-
tance genes in Acb complex strains isolated in Daejeon, Ko-
rea. In the present study, we aimed to determine the genetic 
basis for multidrug resistance and the clonal relatedness of 
the Acb complex clinical isolates obtained from a university 
hospital in Daejeon. Molecular determinants enabling the 
multidrug resistant strains to exhibit co-resistance to car-
bapenems, aminoglycosides, and fluoroquinolones were in-
vestigated with a focus on integrons, carbapenemases, AMEs, 
16S rRNA methylase, and mutations of the gyrA and parC 
genes. 
MATERIALS AND METHODS
1. Bacterial isolates and rpoB gene analysis
A total of 56 consecutive and non-duplicate imipenem-
nonsusceptible Acb complex isolates were collected from 
the university hospital laboratory in Daejeon, Korea, from 
January 2008 to December 2010. Acinetobacter spp. were 
identified by using the Vitek 2
® automated ID system (Bio-
Mérieux, Marcy l’Etoile, France) and partial sequencing of 
the rpoB housekeeping gene, as described previously [13]. 
2.   Antimicrobial agents and minimum inhibitory 
concentration (MIC) determinations
The MICs of Acb complex isolates for imipenem, merope-
nem, gentamicin, amikacin, ceftazidime, cefepime, and cip-
rofloxacin were determined using Etest (BioMérieux). In-
terpretation was based on the criteria approved by the CLSI 
[14]. Escherichia coli ATCC 25922 was used as the reference 
strain. 
3.   Characterization of antimicrobial resistance 
determinants
All Acb complex isolates were subjected to PCR and se-
quencing assays for the detection of antimicrobial resistance 
determinants and the identification of mutations associated 
with fluoroquinolone resistance. Specific primers for the de-
tection of antimicrobial resistance determinants were used 
[15-18]. Chromosomal DNA was obtained from each target 
strain by using a genomic DNA purification kit (Promega, 
Madison, WI, USA) in accordance with standard protocols. 
PCR was performed using 50 ng of genomic DNA, 2.5 µL 
of 10× Taq buffer, 0.5 µL of 10 mM dNTP mix, 20 pmol of 
each primer, and 0.7 U of Taq DNA polymerase (SolGent, 
Daejeon, Korea), in a total volume of 25 µL. Each antimi-
crobial resistance determinant gene was amplified in a Ge-
neAmp PCR System 9600 thermal cycler (Perkin-Elmer 
Cetus Corp., Norwalk, CT, USA) by pre-denaturation of the 
reaction mixture at 95˚C for 5 min, followed by 35 cycles of 
95˚C for 30 sec, 52˚C for 40 sec, and 72˚C for 30 sec, with a 
final extension at 72˚C for 5 min. The amplicons were puri-
fied with a PCR purification kit (SolGent) and were sequen-
ced using a BigDye Terminator Cycle Sequencing Kit (PE 
Applied Biosystems, Foster City, CA, USA) and an ABI PR-
ISM 3730XL DNA analyzer (PE Applied Biosystems). Inte-
gron detection, characterization, and gene cassette amplifi-
cation were carried out using previously described PCR me-
thods [19].
4.   Repetitive extragenic palindromic PCR (REP-PCR) for 
clonality assessment
In the REP-PCR method, the primer pair of REP1 (5´- 
IIIGCGCCGICATCAGGC-3´) and REP2 (5´-ACGTCT-
TATCAGGCCTAC-3´) was used to amplify putative REP-
like elements in the genomic DNA [20]. Amplification reac-
tions were performed in a final volume of 50 µL, containing 
100 ng of chromosomal DNA, 5 µL of 10× Taq buffer, 1.0 
µL of 10 mM dNTP mix, 1.5 U of Taq DNA polymerase 
(SolGent), and 50 pmol of each primer. The cycling condi-
tions were as follows: an initial denaturation step at 95˚C for 
5 min; followed by 30 cycles of 92˚C for 50 sec, 48˚C for 55 
sec, and 70˚C for 5 min; and a final extension step at 70˚C 
for 10 min. The amplified products were separated via elec-
trophoresis on 1.5% agarose gels containing ethidium bro-Sung JY, et al.  •  Antimicrobial Resistance Genes in Acb Complex 
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mide, and visualized using a BioDoc-14
TM Imaging system 
(UVP, Cambridge, UK). 
RESULTS
1. Identification of Acinetobacter spp
Isolates were assigned to 3 distinct Acinetobacter species 
on the basis of the results of rpoB gene analysis: A. bauman-
nii (N=44), Acinetobacter gen. sp. 3 (N=10), and Acineto-
bacter gen. sp. 13TU (N=2). The distribution of MICs for 
imipenem, meropenem, amikacin, ceftazidime, and cefepi  me 
was similar among A. baumannii, Acinetobacter gen. sp. 3, 
and Acinetobacter gen. sp. 13TU. However, high-level resis-
tance to gentamicin (MIC50≥1,024 mg/L) and ciprofloxacin 
(MIC50≥32 mg/L) was only seen in the A. baumannii iso-
lates (Table 1).
2. Detection and characterization of integrons
Most of the Acb complex isolates (94.6%) contained class 
1 integrons, which ranged between 1.8 and 3.0 kb in length. 
However, no class 2 or class 3 integrons were found within 
the cohorts. The gene cassettes found in this study were di-
vided into 4 types by nucleotide sequencing (Fig. 1). The 
type 1 amplicon (3.0 kb), obtained in 10 Acinetobacter gen. 
sp. 3 isolates, carried aacA4-blaIMP-1-blaOXA-2 gene cassettes. 
The type 2 amplicon (3.0 kb), found in 2 Acinetobacter gen. 
sp. 13TU isolates, carried blaVIM-2-aacA7-aadA1 gene cas-
settes. The type 3 amplicon (1.8 kb), detected in only 1 Aci-
netobacter gen. sp. 13TU isolate, carried aac3-1-blaOXA-2-orfD 
gene cassettes. Forty-one A. baumannii isolates (93.2%) con-
tained the type 4 amplicon (2.3 kb) carrying aacA4-catB8-
aadA1 gene cassettes. 
3. Carbapenem resistance genes in Acb complex isolates
The distribution of carbapenem resistance genes among 
isolates of the 3 different Acinetobacter species is shown in 
Table 2. The blaOXA-23 gene was only amplified from 21 A. 
baumannii isolates (47.7%), all of which harbored the up-
stream insertion element ISAba1 and were highly resistant 
to imipenem (MICs≥32). The intrinsic β-lactamase gene, 
blaOXA-51-like, was amplified in all 44 A. baumannii isolates, 
and an upstream ISAba1 was identified in 39 strains (88.6%). 
Other OXA-type carbapenemase genes, such as blaOXA-24 and 
blaOXA-58-like, were not found in this study. 
Two MBL genes, blaIMP-1 and blaVIM-2, were detected in 
Acinetobacter gen. sp. 3 and 13TU. The blaSIM gene was not 
detected in any of our isolates. All imipenem-nonsuscepti-
ble Acb complex isolates contained more than 1 carbapene-
mase gene.
4.   Aminoglycoside resistance genes in Acb complex 
isolates
Three different genes encoding AMEs were identified: 
aac(6´)-Ib was the most prevalent, found in 52 isolates, fol-
lowed by aph(3´)-Ia in 31 isolates, and aph(3´)-VI in 12 iso-
Table 1. The MIC distribution of 7 antimicrobial agents for the 56 A. calco-
aceticus-baumannii complex isolates as determined by Etest
Antimicrobial 
agents
MIC (mg/L)
A. baumannii 
(N=44) 
Acinetobacter genomic species 
3 and 13TU (N=12)
Range  MIC50 MIC90 Range MIC50 MIC90
Amikacin 4 to >256  >256 >256 48 to >256  >256 >256
Gentamicin 8 to >1,024  >1,024 >1,024 8 to 128        64       128
Ceftazidime 128 to >256 >256 >256 64 to >256 >256 >256
Cefepime      8 to 192       32       192      4 to 64       32       64
Imipenem 8 to >32 >32 >32 8 to >32 >32 >32
Meropenem 8 to >32 >32 >32     8 to >32 >32 >32
Ciprofloxacin >32 >32 >32 0.19 to >4       4       4
Abbreviation: MIC, minimum inhibitory concentration.
Type 1 Intl 1 aacA4 blaIMP-1 blaOXA-2 qacEΔ1
5´ CS
5´ CS
5´ CS
5´ CS
3´ CS
3´ CS
3´ CS
3´ CS
Intl 1 blaVIM-2 aacA7 aadA1 qacEΔ1
Intl 1 aac3-1 blaOXA-2 orfD qacEΔ1
Intl 1 aacA4 catB8 aadA1 qacEΔ1
Type 2
Type 3
Type 4
Fig. 1. Schematic representation of gene cassette structures located in the 
class 1 integron isolated from Acinetobacter calcoaceticus-baumannii complex 
isolates. The horizontal arrows indicate the translation orientation of the genes.
Table 2. Distribution of carbapenemase genes in imipenem-nonsusceptible 
Acinetobacter calcoaceticus-baumannii complex isolates
Genomic species
N of genes
blaIMP-1 blaVIM-2 blaOXA-23 blaOXA-51-
like
A. baumannii (N=44) 21 44
Acinetobacter genomic species 3 (N=10) 10
Acinetobacter genomic species 13TU (N=2) 2
Total (N=56) 10 2 21 44268     www.kjlm.org
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lates (Table 3). All 10 Acinetobacter gen. sp. 3 isolates con-
tained aac(6´)-Ib and aph(3´)-VI, whereas 31 A. baumannii 
isolates had the combination of aac(6´)-Ib/aph(3´)-Ia. The 
16S rRNA methylase gene armA was detected in 41 A. bau-
mannii isolates, but rmtA and rmtB were not detected in any 
Acb complex isolates tested. The 41 A. baumannii isolates 
containing armA were highly resistant to amikacin (MIC50≥ 
256 mg/L) and gentamicin (MIC50≥1,024 mg/L). 
The 3 A. baumannii isolates that did not contain integrons 
or 16S rRNA methylase and AMEs had low-level aminogly-
coside resistance, with an amikacin MIC50 of 4 mg/L and a 
gentamicin MIC50 of 8 mg/L.
5.   Characterization of quinolone resistance among Acb 
complex isolates
All A. baumannii isolates had sense mutations at the 83rd 
residue (serine to leucine) in gyrA and at the 80th residue 
(serine to leucine or tryptophan) in parC, and had high-level 
ciprofloxacin resistance (MIC50≥32 mg/L). However, sense 
mutations in parC were not detected in Acinetobacter gen. 
sp. 3 and 13TU isolates. The sense mutations at the 83rd 
residue (serine to leucine) in gyrA were detected in only 8 
Acinetobacter gen. sp. 3 isolates, which had low-level cipro-
floxacin resistance (MIC50=4 mg/L). The 3 Acinetobacter 
gen. sp. isolates without sense mutations in either gyrA or 
parC were susceptible to ciprofloxacin (MIC50=0.19 mg/L).
6. REP-PCR patterns
To determine the clonality of all 56 Acb complex isolates, 
REP-PCR was performed on genomic DNA. The 44 A. bau-
mannii isolates displayed only 2 REP-PCR types, designated 
type A and type B (Fig. 2). However, the Acinetobacter gen. 
sp. 3 and 13TU isolates showed diverse band patterns.
DISCUSSION
This study analyzed various genes of Acb complex isolates 
that are responsible for resistance to carbapenems, amino-
glycosides, and fluoroquinolones. Previous studies focused 
mainly on carbapenem or aminoglycoside resistance [11]. 
We found differences in the genetic characteristics of iso-
lates from 3 different Acinetobacter species in terms of their 
carbapenem, aminoglycoside, and fluoroquinolone resis-
tance. 
Our study identified several differences in carbapenem 
resistance genes among Acinetobacter spp. isolates. OXA-
type carbapenemase genes (blaOXA-23 and blaOXA-51-like) were 
only observed in A. baumannii isolates, while MBL genes 
(blaIMP-1 or blaVIM-2) were only present in Acinetobacter gen. 
sp. 3 or 13TU isolates. This distribution is in accordance 
with previous reports of resistance genes among Acineto-
bacter spp. [21, 22]. The presence of ISAba1 upstream of 
blaOXA genes provides a promoter sequence enhancing their 
expression [23]. In isolates possessing blaOXA-23, ISAba1 was 
consistently associated with blaOXA-23 and not with the bla-
OXA-51-like gene, suggesting that coexpression of these 2 genes 
does not occur. The dissemination of A. baumannii isolates 
harboring the blaOXA-23 gene has been previously reported in 
Korea [15, 24]. In addition, class 1 integrons harboring MBL 
genes were detected in Acinetobacter gen. sp. 3 and 13TU 
isolates. A 3.0-kb class 1 integron containing blaIMP-1 with 
Table 3. Distribution of aminoglycoside resistance genes in imipenem-non-
susceptible Acinetobacter calcoaceticus-baumannii complex isolates
Genomic species
N of genes
armA aac(6’)-
Ib
aph(3’)-
Ia
aph(3’)-
VI
A. baumannii (N=44) 41 41 31
Acinetobacter genomic species 3 (N=10) 10 10
Acinetobacter genomic species 13TU (N=2) 1 2
Total (N=56) 41 52 31 12
M  Ab  Ag  Ab  Ab  Ab  Ab  Ab  Ag  M  Ab  Ab  Ab  Ab  Ab  Ab  Ab  Ab  Ag  Ab  Ag
12,000
A A A A A A A A A A A A A A B
5,000
3,000
2,000
1,000
500
100
Fig. 2. Repetitive extragenic palindromic (REP)-PCR patterns of genomic DNA from imipenem-nonsusceptible Acinetobacter calcoaceticus-baumannii complex iso-
lates. Lane M, 1-kb DNA size marker; Ab, Acinetobacter baumannii; Ag, Acinetobacter genomic species 3.Sung JY, et al.  •  Antimicrobial Resistance Genes in Acb Complex 
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aacA4 and blaOXA-2 was described in A. baumannii (EF375699) 
and A. junii (EU014166) isolates recovered from Korea in 
2007. In our previous study, we reported that multidrug re-
sistant A. baumannii isolates contained class 1 integrons har-
boring blaIMP-1 with aacA4 and blaOXA-2 [15]. However, an A. 
baumannii isolate harboring blaIMP-1 was not detected in the 
present study. A 3.0-kb class 1 integron containing blaVIM-2 
with aacA7 and aadA1 was described in A. baumannii (AF-
324464) recovered from Korea in 2002 [25].
In our study, significant variation was seen in the distri-
bution of aminoglycoside resistance genes among Acineto-
bacter gen. sp. isolates. The armA and aph (3´)-Ia genes were 
only detected in A. baumannii isolates, whereas aph(3´)-VI 
was only detected in Acinetobacter gen. sp. 3 and 13TU iso-
lates. In particular, A. baumannii isolates containing armA 
showed high-level gentamicin resistance (MIC50  ≥1,024 
mg/L). Unlike AMEs, which vary in their substrate ranges, 
16S rRNA methylases confer high-level resistance to almost 
all clinically important aminoglycosides [11]. The armA gene 
was previously detected in A. baumannii, P. aeruginosa, E. 
coli, K. pneumoniae, and S. marcescens [26], but has not been 
detected in other Acinetobacter gen. sp. so far. 
A major mechanism of fluoroquinolone resistance in 
gram-negative bacteria involves changes in the structure of 
the drug targets, DNA gyrase and DNA topoisomerase IV 
[27]. In particular, amino acid substitutions in both the 
GyrA and ParC polypeptides are consistent with a high-level 
fluoroquinolone resistant phenotype [28]. In this study, all 
44 A. baumannii isolates harboring sense mutations in both 
gyrA and parC showed high-level resistance to ciprofloxa-
cin (MIC50 ≥32 mg/L). These results are similar to those re-
ported in our study of multidrug resistant A. baumannii 
isolates [15]. 
In addition, identical banding patterns on REP-PCR pro-
files were only seen among the A. baumannii isolates. Our 
results suggest that there is both clonal and horizontal spread 
of resistance genes between imipenem-nonsusceptible A. 
baumannii isolates in the university hospital in Daejeon.
Despite the increasingly frequent discovery of multidrug 
resistant Acinetobacter spp. isolates in Korea, there is a rela-
tive paucity of information regarding the antimicrobial re-
sistance of this gram-negative bacillus in Daejeon. Although 
we found differences in genetic characteristics of isolates 
from 3 different Acinetobacter species, most (87.5%) of them 
possessed integrons, AMEs, carbapenemases, and mutations 
in gyrA. The co-occurrence of several resistance determi-
nants may present a significant threat. 
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